Los puntos clave no están disponibles para este artículo en este momento.
Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Turner et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d8d15017a1cc0598d18a0e — DOI: https://doi.org/10.1056/nejmoa1810527
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Nicholas C. Turner
Dennis J. Slamon
Jungsil Ro
New England Journal of Medicine
University of Pennsylvania
University of California, Los Angeles
The University of Melbourne
Building similarity graph...
Analyzing shared references across papers
Loading...